Jul 2022 $23 M No. 3 $10 to $50 million 36
Biopharmaceutical Research Co: Raise no. 3, Jul 2022 × Investors in this round 36 investors had bought by the notice of Jun 20, 2023: 36 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $23 M of $23 M offered
Smallest investment taken no minimum stated
What was sold equity, other: Total Offering Amount includes the amount related to the conversion of notes into shares of Series A Preferred Stock. The issuance of such convertible notes was reported in September 2020 as a debt an Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,191,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice George Bennett Hodgin · Executive Officer, Director Charles Bennett Schumacher · Director Edward Howard Goodwin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round North Point Mergers and Acquisitions, Inc. (CRD 133300) · San Francisco, California Sold in AZ, CA, CT, GA, KS, LA, MA, NC, NJ, NY, PA, TN, TX, WA Signed by George Bennett Hodgin, Chief Executive Officer. Newest notice filed Jun 20, 2023 (1 amendment). Read the notice at the SEC .
equity SEC Feb 2022 $3 M No. 2 $2 to $10 million 22
Biopharmaceutical Research Co: Raise no. 2, Feb 2022 × Investors in this round 22 investors had bought by the notice of Mar 18, 2022: 22 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $5 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $152,130
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice George Hodgin · Executive Officer, Director Charles Schumacher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round North Point Mergers and Acquisitions, Inc. (CRD 133300) · San Francisco, California Sold in CA, CT, KS, LA, MA, NC, NJ, NY, TN, TX Remarks in the notice On fees: “North Point Mergers and Acquisitions, Inc. will receive equity private placement fees corresponding to (i) a cash fee of 6% of the total investments and (ii) warrants representing 3% of the total investments.”Signed by George Hodgin, Chief Executive Officer. Newest notice filed Mar 18, 2022 (1 amendment). Read the notice at the SEC .
equity, options SEC Sep 2020 $2 M No. 1 $2 to $10 million 17
Biopharmaceutical Research Co: Raise no. 1, Sep 2020 × Investors in this round 17 investors had bought by the notice of Oct 2, 2020: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $3 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $122,700
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice George Hodgin · Executive Officer, Director Charles Schumacher · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round North Point Advisors, Inc. (CRD 133300) · broker-dealer North Point Advisors, Inc. (CRD 133300) · San Francisco, California Sold in AZ, CA, CO, CT, DC, HI, IL, MA, MI, NC, NJ, NY, PA, PR, TX, UT, WA Remarks in the notice On fees: “North Point Advisors, Inc. will also receive a to be determined number of warrants to purchase shares of the issuer.”Signed by George Hodgin, Chief Executive Officer. Newest notice filed Oct 2, 2020. Read the notice at the SEC .
debt, options SEC